The difference between feeling better and getting better.

FDA-approved Adequan® Canine is back in our pack of joint health products. Ask your veterinarian if Adequan Canine is the right choice for controlling the clinical signs of your dog’s arthritis.

As the manufacturer of Adequan® Canine (polysulfated glycosaminoglycan) for more than 20 years, Luitpold Pharmaceuticals has advanced joint health for thousands of dogs, helping them get back to being active by controlling the signs of canine arthritis. Now, as of April 1, 2018, Adequan Canine is back in the Luitpold Animal Health (LAH) product portfolio. We’ve lined up distributor partners and will also be providing customer and technical support directly as needed.

Restore. Relieve. Renew.

The FDA-approved formula that’s never been duplicated.

Adequan® Canine (polysulfated glycosaminoglycan) is the only FDA-approved injectable, disease-modifying osteoarthritis drug (DMOAD) that inhibits cartilage loss in the dog’s joint, and may help to:1
  • Restore joint lubrication

  • Relieve inflammation

  • Renew the building blocks of healthy cartilage

*The specific mechanism of action of Adequan Canine in canine joints is not known.1
Indications
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Important Safety Information
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see Full Prescribing Information.
Talk to your veterinarian about a multi-modal plan that includes daily exercise, weight control and physical therapy.
1. Adequan Canine Prescribing Information, Rev. 1/18.

Start with it. Stay with it.

Adequan Canine Product Box and Vials
Adequan Canine Product Box and Vials

Start with it:

  • Use Adequan Canine early, at the first clinical signs of Degenerative Joint Disease (DJD) before it progresses and cartilage is irreversibly damaged.2

  • Administer twice weekly for up to 4 weeks (maximum of 8 injections).1

  • Should see signs of improvement within a month.2

Stay with it:

Continue to prescribe as needed to control signs of arthritis.

IM delivery provides fast relief and reliable protection.

Within just 2 hours, Adequan Canine reaches all major synovial joints to help restore joint tissues that are damaged or inflamed — and lasts for approximately 3 days.2
The exact mechanism of action in dogs is not known.

A comprehensive plan can help slow the progression of canine arthritis.

Talk to your veterinarian about a multi-modal plan that includes daily exercise, weight control and physical therapy.
1. Adequan® Canine Prescribing Information, Rev. 1/18.
2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 Freedom of Information Summary, 1997.
How To Use Graph

Backed by science. Proven over time.

Reasons to reach for Adequan® Canine first.

  • Prescribed for over 20 years to help control signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

    • Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Efficacy demonstrated in two studies, radiolabeled and clinical field trials.2

2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 Freedom of Information Summary, 1997.
How To Use Graph
Clinical field trials: At the end of the treatment period, dogs treated with Adequan Canine showed a statistically significant improvement in range of motion and total orthopedic score (including assessments of lameness, pain and functional disability) over placebo treated control dogs.2


Want to place
an order?

Contact your Distributor

Call Luitpold Animal Health Customer Service at 800-458-0163

Mobile Icon
LAH Team
800-458-0163
Mobile Icon
Fax
866-597-1991
Mobile Icon
Mail
One Luitpold Drive
PO Box 9001
Shirley, NY 11967

Report an Adverse Drug Reaction

To report an adverse event for any Luitpold Animal Health product Contact Luitpold Animal Health Toll-free: 800-734-9236 Email: pv@luitpold.com Contact the Center for Veterinary Medicine Web: https://www.fda.gov/AnimalVeterinary/ Toll-Free: 888-FDA-VETS


Report a Product Quality Complaint

To report a product quality complaint for any Luitpold Animal Health product Contact Luitpold Animal Health Toll-free: 888-354-4859 Email: PQC@luitpold.com

Medical Affairs Drug Information

Toll-free: 888-354-4855
9 am-5 pm ET, Monday-Friday
Email: ma@luitpold.com








Indications
Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Important Safety Information
Adequan® Canine should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. For additional safety information, please see Full Prescribing Information.
*The exact mechanism of action in dogs is not known.
1. Adequan® Canine Prescribing Information, Rev. 1/18.
2. Adequan® Canine (polysulfated glycosaminoglycan) NADA 141-038 Freedom of Information Summary, 1997.

Adequan® and the Dog Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
© 2018 Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc.
PP-AC-US-0004 4/2018
Click here to learn how Adequan® may also help horses with Degenerative Joint Disease (DJD).


Adequan® and the Dog Head design are registered trademarks of Luitpold Pharmaceuticals, Inc.
One Luitpold Drive, PO Box 9001, Shirley, NY 11967   |   800-458-0163   |   info@adequan.com
© 2018 Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc.     PP-AC-US-0004 (v3.0) 4/2018